104 related articles for article (PubMed ID: 31182881)
1. [Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo].
Valle-Solís AE; Miranda-Aguirre AP; Mora-Pérez J; Pineda-Juárez JA; Gallardo-Valencia LE; Santana L; Cervantes-Sanchez G; Cárdenas-Cárdenas E
Gac Med Mex; 2019; 155(Suppl 1):S50-S55. PubMed ID: 31182881
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer survival by immunohistochemistry-determined subtype: A retrospective study.
Valle-Solís AE; Miranda-Aguirre AP; Mora-Pérez J; Pineda-Juárez JA; Gallardo-Valencia LE; Santana L; Cervantes-Sánchez G; Cárdenas-Cárdenas E
Gac Med Mex; 2019; 155(Suppl 1):S39-S43. PubMed ID: 31638609
[TBL] [Abstract][Full Text] [Related]
3. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
4. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
5. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype.
Cruz Ciria S; Jiménez Aragón F; García Mur C; Esteban Cuesta H; Gros Bañeres B
Radiologia; 2014; 56(6):524-32. PubMed ID: 23294850
[TBL] [Abstract][Full Text] [Related]
7. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
García Fernández A; Giménez N; Fraile M; González S; Chabrera C; Torras M; González C; Salas A; Barco I; Cirera L; Cambra MJ; Veloso E; Pessarrodona A
Breast; 2012 Jun; 21(3):366-73. PubMed ID: 22487206
[TBL] [Abstract][Full Text] [Related]
8. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
10. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
Ogiya R; Sagara Y; Niikura N; Freedman RA
Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
[TBL] [Abstract][Full Text] [Related]
11. Does IBD Portend Worse Outcomes in Patients with Rectal Cancer? A Case-Matched Analysis.
Alsughayer A; Grass F; McKenna NP; Petersen M; Mathis KL; Lightner AL
Dis Colon Rectum; 2020 Sep; 63(9):1265-1275. PubMed ID: 33216497
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
14. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
17. Perineural Invasion Is a Prognostic but not a Predictive Factor in Nonmetastatic Colon Cancer.
Leijssen LGJ; Dinaux AM; Taylor MS; Deshpande V; Kunitake H; Bordeianou LG; Berger DL
Dis Colon Rectum; 2019 Oct; 62(10):1212-1221. PubMed ID: 31490830
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
19. [Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social].
Pérez-Rodríguez G
Cir Cir; 2015; 83(3):193-8. PubMed ID: 26055281
[TBL] [Abstract][Full Text] [Related]
20. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]